Found 33 Lymphoma trials
A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using …
The primary objective of this study is to evaluate the safety of retreatment of patients with CTL019/CTL119 therapy who have experienced late relapse of lymphoma.
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release. The primary purpose of a MAP is to provide access to product. NA - …
Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints)
The purpose of this trial is to evaluate the safety and efficacy of 18 weeks of HyBryte treatment in combination with visible light therapy in subjects 18 years and older with cutaneous T-cell lymphoma when compared to placebo. Procedures include vital signs, physical examination, review of medical history, blood tests, …
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints).
To compare the progression-free survival in participants with relapsed/refractory large B-cell lymphoma or follicular lymphoma grade 3B with stable disease (SD) or partial remission (PR) on first imaging response by central review (day +30PET/CT scan) after commercial CD19 CAR T-cell therapy
Patients with plasmablastic lymphoma are potential participants of this research trial. Patients with a type of B-cell non-Hodgkin lymphoma (NHL) will be invited from Penn Medicine practices. This research study is designed to test the safety of daratumumab, a drug added to the standard lymphoma treatment when given to individuals …
